$44.24
-0.88[-1.95%]
At close: May 28
$44.24
0[0.00%]
After Hours: 6:19PM EDT
Latest News for GSK Stock (NYSE:GSK)
GSK Stock (NYSE: GSK)
Categories: All
Monday, May 27, 2024
Friday, May 24, 2024
Thursday, May 23, 2024
Wednesday, May 22, 2024
Tuesday, May 21, 2024
- GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit ClaimsVandana Singh - May 21, 2024, 12:48PM
- GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data ShowsVandana Singh - May 21, 2024, 8:31AM
- GSK's Phase 3 Trials SWIFT-1 and SWIFT-2 Of Depemokimab Versus Placebo In Severe Asthma Patients With Type 2 Inflammation Met Primary Endpoints Of Reduction In Annualized Rate Of Clinically Significant Exacerbations (Asthma Attacks) Over 52 WeeksBenzinga Newsdesk - May 21, 2024, 5:37AM
Friday, May 17, 2024
Thursday, May 16, 2024
Monday, May 13, 2024
Friday, May 10, 2024
Thursday, May 09, 2024
Wednesday, May 08, 2024
Tuesday, May 07, 2024
Wednesday, May 01, 2024
- GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual OutlookVandana Singh - May 1, 2024, 9:42AM
- Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer RallyShanthi Rexaline - May 1, 2024, 6:44AM
- GSK shares are trading higher as the company reported better-than-expected Q1 results and raised its 2024 core operating profit guidance.Benzinga Newsdesk - May 1, 2024, 6:13AM
- GSK Expects 2024 Core EPS To Increase Between 8% To 10% Versus Prior Guidance Of Increase Between 6% To 9%Benzinga Newsdesk - May 1, 2024, 5:34AM
- GSK Expects 2024 Core Operating Profit To Increase Between 9% To 11% Versus Prior Guidance Of Increase Between 7% To 10%Benzinga Newsdesk - May 1, 2024, 5:33AM
- GSK Expects 2024 Sales To Increase Towards The Upper Part Of The Range Of Between 5% To 7%, Versus Previous Guidance Of Increase Of 5%-7%Benzinga Newsdesk - May 1, 2024, 5:32AM
- GSK Q1 Adj. EPS $1.09 Beats $0.91 Estimate, Sales $9.33B Beat $8.92B EstimateBenzinga Newsdesk - May 1, 2024, 3:52AM
Monday, April 29, 2024
Friday, April 26, 2024
Thursday, April 25, 2024
Wednesday, April 24, 2024
- CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza VirusBenzinga Newsdesk - Apr 24, 2024, 7:20AM
- CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of HealthBenzinga Newsdesk - Apr 24, 2024, 7:18AM
- The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial CancerBenzinga Newsdesk - Apr 24, 2024, 6:58AM
Tuesday, April 23, 2024
Monday, April 22, 2024
Friday, April 19, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
- GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 YearsVandana Singh - Apr 17, 2024, 8:06AM
- GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital GonorrheaBenzinga Newsdesk - Apr 17, 2024, 5:32AM
- GSK Says New Long-Term Data Show Shingrix Continues To Provide Protection Against Shingles In Adults Aged 50 And Over For More Than A DecadeBenzinga Newsdesk - Apr 17, 2024, 5:30AM
Thursday, April 11, 2024
Thursday, April 04, 2024
- CureVac, GSK Partner Release Data On Influenza Vaccine StudyVandana Singh - Apr 4, 2024, 12:18PM
- In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit ClusterVandana Singh - Apr 4, 2024, 9:16AM
- CureVac Announces Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKBenzinga Newsdesk - Apr 4, 2024, 7:07AM
Tuesday, March 26, 2024
Thursday, March 21, 2024
Monday, March 18, 2024
- U.S. CDC Issues Health Alert Network Health Advisory On Increase In Global And Domestic Measles Cases And Outbreaks; Says Ensure Children In The United States And Those Traveling Internationally 6 Months And Older Are Current On MMR VaccinationBenzinga Newsdesk - Mar 18, 2024, 1:54PM
- GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial CancerVandana Singh - Mar 18, 2024, 12:17PM
- Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2BVandana Singh - Mar 18, 2024, 12:08PM
- Reported Saturday, GSK Announced RUBY Phase III Data Show Potential For Jemperli (Dostarlimab-Gxly) Combinations In More Patients With Primary Advanced Or Recurrent Endometrial CancerBenzinga Newsdesk - Mar 18, 2024, 2:35AM